WO2003047533A2 - Composition pour le traitement de la surface de la peau - Google Patents

Composition pour le traitement de la surface de la peau Download PDF

Info

Publication number
WO2003047533A2
WO2003047533A2 PCT/DE2002/004372 DE0204372W WO03047533A2 WO 2003047533 A2 WO2003047533 A2 WO 2003047533A2 DE 0204372 W DE0204372 W DE 0204372W WO 03047533 A2 WO03047533 A2 WO 03047533A2
Authority
WO
WIPO (PCT)
Prior art keywords
composition according
skin
mixture
microorganisms
composition
Prior art date
Application number
PCT/DE2002/004372
Other languages
German (de)
English (en)
Other versions
WO2003047533A3 (fr
Inventor
Christian Uphoff
Original Assignee
Umwelttechnik Georg Fritzmeier Gmbh & Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Umwelttechnik Georg Fritzmeier Gmbh & Co. filed Critical Umwelttechnik Georg Fritzmeier Gmbh & Co.
Priority to AU2002365621A priority Critical patent/AU2002365621A1/en
Publication of WO2003047533A2 publication Critical patent/WO2003047533A2/fr
Publication of WO2003047533A3 publication Critical patent/WO2003047533A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/748—Cyanobacteria, i.e. blue-green bacteria or blue-green algae, e.g. spirulina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/534—Mentha (mint)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/537—Salvia (sage)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/68—Plantaginaceae (Plantain Family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/734—Crataegus (hawthorn)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/736—Chitin; Chitosan; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/42—Colour properties
    • A61K2800/43—Pigments; Dyes
    • A61K2800/434—Luminescent, Fluorescent; Optical brighteners; Photosensitizers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/75—Anti-irritant

Definitions

  • composition for the treatment of the skin surface Composition for the treatment of the skin surface
  • the present invention relates to a composition for treating the skin surface and the use of this composition for the treatment of changes in the skin.
  • the surface of the skin is not completely smooth, but locally furrowed with furrows, wrinkles and wrinkles.
  • the skin relief is particularly characteristic on the fingers, palms and soles of the feet.
  • the skin is regarded primarily as protection of the body, which in itself has various mechanisms for its own protection and can also activate accordingly.
  • skin changes often occur due to diseases such as scars, warts, acne, dandruff, lichen, psoriasis, eczema and other skin conditions. Often these are due to environmental influences.
  • the sufferers not only suffer physically, z. As itching, but also psychologically by the excruciating itching and scratching the skin with sometimes severe bleeding.
  • the above-mentioned agents are synthetic products of the pharmaceutical industry. It is known that they cause significant side effects. Often it is the case that the skin no longer reacts to frequent use of these agents, since, for example, fungi / bacteria are known to be resistant to such substances.
  • the present invention therefore relates to a skin surface treatment composition
  • a skin surface treatment composition comprising a mixture of photosynthetic microorganisms and luminescent bacteria. It is preferred if the composition contains a chitin-based polysaccharide in aqueous solution.
  • the subclaims further relate to the use of this composition for the treatment of changes in the skin.
  • the invention further relates to the use of this composition for the treatment of changes in the skin.
  • the composition contains two groups of microorganisms.
  • the interplay between the photosynthetic microorganisms and the luminescent bacteria leads to photosynthetic microorganisms being stimulated by the luminescent bacteria to photosynthesize.
  • the microorganisms operate photosynthesis with hydrogen sulfide and water as adduct and release sulfur or oxygen. They can also bind nitrogen as well as phosphate and degrade organic and inorganic matter.
  • photosynthetic microorganisms are used, which are optionally phototrophic.
  • Phototrophic optional means that the microorganisms can grow in the dark under both anaerobic conditions in the light and under aerobic conditions.
  • the photosynthetic bacteria include gram-negative aerobic, rod-shaped and circular bacteria as well as gram-positive circular bacteria. these can
  • composition according to the invention for treating the skin surface preferably contains in the mixture as optionally photoprobe microorganisms prochlorophytes, cyanobacteria, green sulfur bacteria, purple bacteria, chloroflexus-like forms and heliobacteria or Heliobacillus-like forms and mixtures of two or more thereof.
  • all six mentioned microorganisms are present as a mixture.
  • the light that drives photosynthesis is from the luminescent bacteria contained as a second essential component in the microorganism composition of the present invention.
  • These luminescent bacteria have a luminosity, that is, they are able to emit light quanta. It is a system that is enzymatic; as an example the luciferin-luciferase system can be mentioned.
  • photobacterium phosphoreum, Vibrio fischeri, Vibrio harveyi, Pseudomonas lucifera or Beneckea or mixtures of at least two are contained in the mixture according to the invention as luminescent bacteria.
  • a third essential component of the skin surface treatment composition of the present invention is the chitin-based polysaccharide.
  • Chitosan is preferably used as the chitin-based polysaccharide. This is the weakly basic, deacetylated and partially depolymerized crystalline chitosan, which has quite good dissolution properties.
  • herbal extracts may furthermore be present.
  • any mixture of herbs can be used here, as long as the effect of the composition according to the invention is not impaired.
  • a herbal extract of plantain, hawthorn, sage, nettle, wild berry, birch or mint is particularly supportive.
  • mixtures of the said herbs can be used, in which case at least two are present.
  • composition according to the invention may contain as further active component an enzyme or an enzyme mixture. It has been found that preferably those enzymes or enzyme mixtures are suitable which originate from pineapple comosus, Carica papaya and / or pancreas. As examples may be mentioned papain, protease, trypsin, chymotrypsin, bromelain or rutoside. In particular, a mixture containing at least two of said enzymes is added.
  • Be contained in the composition include, preferably, sodium, manganese, copper, boron, zinc, iron, sulfur, magnesium, potassium, calcium, phosphate or mixtures thereof.
  • salts are preferably additionally incorporated. These are, for example, salts of alkali metals, alkaline earth metals and other metals.
  • the anions used are preferably the chlorides, bromides, carbonates, bicarbonates, sulfates, hydrogen phosphates, fluorides and / or iodides of these metals.
  • alkaline earth metals alkali metals and other metals, in cationic form, for example, calcium, magnesium, sodium, calcium, iron, ammonium, strontium and manganese.
  • composition of the invention may also contain silica.
  • the photosynthetic microorganisms and the luminescent bacteria in a ratio of 1: 10 to 1: 500, preferably 1: 100, contained in the inventive composition.
  • the concentration of the bacteria, based on the composition preferably in a range of 2-3%.
  • the ratio of the amount of microorganisms to chitin-based polysaccharide ranges from about 70:30 to 95: 5. A range of 90:10 is preferred here.
  • alginates such as alginates, which are used for 02 production.
  • other microorganisms may also be present which exert a positive effect on the composition according to the invention.
  • lactic acid bacteria are used.
  • the solution containing the components of the composition of the invention is an aqueous solution, that is, an aqueous, physiological solution.
  • the treatment of the affected skin areas can be carried out particularly effectively if the composition contains microorganisms which release photosensitizers, which can then be incorporated into the diseased cells. Upon exposure to light, these photosensitizers are then activated to produce singlet oxygen or other reactive radicals which, through oxidation and reduction processes, ablate the cells of the affected skin area. In principle, it is also possible to add the photosensitizers directly to the composition.
  • the invention according to the composition is absolutely a biological product that can be applied to the skin with good success, without the risk of side effects. It works effectively in the treatment of changes in the skin.
  • the changes in the skin are usually due to the fact that the skin is damaged by environmental influences. This includes the fungal and bacterial attack of the skin. It is known that, for example in athlete's foot, the skin itches to itch and shed the top layers of the skin like scales.
  • composition according to the invention can also be any indifferent general skin itching effectively with the present be treated composition according to the invention.
  • the composition of the invention has also been successful in the treatment of rashes. So even extremely dry skin with possibly dandruff can be successfully treated.
  • application of the composition according to the invention in eczema, especially in the arm and squat, has brought rapid and long-lasting relief.
  • composition according to the invention can be applied in any dosage form which is suitable for application to the skin. Examples include tincture, ointment, cream and lotion.
  • the composition of the invention may also be present in bath or shower additives. It goes without saying that the composition according to the invention is processed with the customary additives for the mentioned dosage forms.
  • composition according to the invention can be prepared, for example, as follows.
  • Suitable microorganisms for producing photosensitizers are, for example, bacteriochlorophyll, Monascus purpurus (Pigment 3658), Limicola-Nadson (cell dye 2145) or Pseudomonas fluorescene.
  • bacteriochlorophyll results in a chlorophyll A reaction, upon irradiation with light bacterial release of aminolevulinic acid, forming protoporphyrin IX (PPIX), which is selectively taken up and stored by the affected cells.
  • PPIX protoporphyrin IX
  • This PPIX is then activated by exposure to light, and as a result of the photodynamic effects of electron transfer, the above-described formation of singlet oxygen and radicals within the cell occurs, which are then broken up and damaged by oxidation and reduction processes.
  • the destruction of the cells can then be done in two ways, done by necrosis or apoptosis.
  • the principal efficiency of the photodynamic process can be defined by the following steps:
  • composition of the invention may also be present as a set.
  • a container may contain the microorganisms, herbal extracts and chitin-based polysaccharide.
  • the salt and the enzyme or the enzyme mixture are filled. The user can then use a suitable instructions for its composition for Make the skin surface yourself and apply immediately to the affected skin.
  • a skin surface treating composition comprising a mixture of photosynthetic microorganisms and luminescent bacteria and a chitin-based polysaccharide in aqueous solution.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne une composition pour le traitement de la surface de la peau, laquelle contient un mélange constitué de micro-organismes agissant par photosynthèse et de bactéries lumineuses, ainsi qu'un polysaccharide à base de chitine en solution aqueuse.
PCT/DE2002/004372 2001-11-29 2002-11-28 Composition pour le traitement de la surface de la peau WO2003047533A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002365621A AU2002365621A1 (en) 2001-11-29 2002-11-28 Composition for treating the surface of the skin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10158712A DE10158712A1 (de) 2001-11-29 2001-11-29 Zusammensetzung zur Behandlung der Hautoberfläche
DE10158712.0 2001-11-29

Publications (2)

Publication Number Publication Date
WO2003047533A2 true WO2003047533A2 (fr) 2003-06-12
WO2003047533A3 WO2003047533A3 (fr) 2003-10-16

Family

ID=7707471

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2002/004372 WO2003047533A2 (fr) 2001-11-29 2002-11-28 Composition pour le traitement de la surface de la peau

Country Status (3)

Country Link
AU (1) AU2002365621A1 (fr)
DE (1) DE10158712A1 (fr)
WO (1) WO2003047533A2 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2924021A1 (fr) * 2007-11-27 2009-05-29 Du Vernet Michele Eymard Composition pour le traitement de la peau par therapie photodynamique
CN103641926A (zh) * 2013-12-05 2014-03-19 淮海工学院 一种山楂叶多糖的提取方法
WO2017184601A1 (fr) * 2016-04-19 2017-10-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Utilisation d'espèces à gram négatif pour traiter la dermatite atopique
US10293005B2 (en) 2016-04-19 2019-05-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of gram negative species to treat atopic dermatitis
US10973841B2 (en) 2018-05-11 2021-04-13 Forte Subsidiary, Inc. Compositions for the treatment of skin conditions

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004060246A1 (de) * 2004-12-15 2006-07-06 Cognis Ip Management Gmbh Verwendung von Chitosan gegen Juckreiz

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6379702B1 (en) * 2000-07-05 2002-04-30 Hydromer, Inc. Gels formed by the interaction of polyvinylpyrrolidone with chitosan derivatives
US6444797B1 (en) * 2000-07-18 2002-09-03 Ibeks Technologies Co., Ltd. Chitosan microflake and method of manufacturing the same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6379702B1 (en) * 2000-07-05 2002-04-30 Hydromer, Inc. Gels formed by the interaction of polyvinylpyrrolidone with chitosan derivatives
US6444797B1 (en) * 2000-07-18 2002-09-03 Ibeks Technologies Co., Ltd. Chitosan microflake and method of manufacturing the same

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2924021A1 (fr) * 2007-11-27 2009-05-29 Du Vernet Michele Eymard Composition pour le traitement de la peau par therapie photodynamique
WO2009095568A2 (fr) * 2007-11-27 2009-08-06 Eymard Du Vernet Michele Composition pour le traitement photodynamique de la peau
WO2009095568A3 (fr) * 2007-11-27 2009-10-15 Eymard Du Vernet Michele Composition pour le traitement photodynamique de la peau
CN103641926A (zh) * 2013-12-05 2014-03-19 淮海工学院 一种山楂叶多糖的提取方法
JP2019513769A (ja) * 2016-04-19 2019-05-30 ザ ユナイテッド ステイツ オブ アメリカ，アズ レプリゼンテッド バイ ザ セクレタリー，デパートメント オブ ヘルス アンド ヒューマン サービシーズ アトピー性皮膚炎を処置するためのグラム陰性種の使用
US10500238B2 (en) 2016-04-19 2019-12-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of gram negative species to treat atopic dermatitis
CN109310626A (zh) * 2016-04-19 2019-02-05 美利坚合众国,由健康及人类服务部部长代表 革兰氏阴性种治疗特应性皮炎的用途
US10195236B2 (en) 2016-04-19 2019-02-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of gram negative species to treat atopic dermatitis
US10206957B2 (en) 2016-04-19 2019-02-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of gram negative species to treat atopic dermatitis
US10293005B2 (en) 2016-04-19 2019-05-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of gram negative species to treat atopic dermatitis
WO2017184601A1 (fr) * 2016-04-19 2017-10-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Utilisation d'espèces à gram négatif pour traiter la dermatite atopique
KR20190003582A (ko) * 2016-04-19 2019-01-09 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 아토피 피부염을 치료하기 위한 그램 음성 종의 용도
US10653727B2 (en) 2016-04-19 2020-05-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of gram negative species to treat atopic dermatitis
US10668114B2 (en) 2016-04-19 2020-06-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of gram negative species to treat atopic dermatitis
US10682379B2 (en) 2016-04-19 2020-06-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of gram negative species to treat atopic dermatitis
US10946048B2 (en) 2016-04-19 2021-03-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of gram negative species to treat atopic dermatitis
US10946049B2 (en) 2016-04-19 2021-03-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of gram negative species to treat atopic dermatitis
KR102340006B1 (ko) 2016-04-19 2021-12-20 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 아토피 피부염을 치료하기 위한 그램 음성 종의 용도
US10980846B2 (en) 2016-04-19 2021-04-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of gram negative species to treat atopic dermatitis
US10973841B2 (en) 2018-05-11 2021-04-13 Forte Subsidiary, Inc. Compositions for the treatment of skin conditions

Also Published As

Publication number Publication date
AU2002365621A1 (en) 2003-06-17
DE10158712A1 (de) 2003-06-26
AU2002365621A8 (en) 2003-06-17
WO2003047533A3 (fr) 2003-10-16

Similar Documents

Publication Publication Date Title
EP0217975B1 (fr) Mélange de sels pour le traitement du psoriasis et autres maladies de la peau
DE60124777T2 (de) Antioxidationsmittel in wassermolekülsammlungen
EP1903003B1 (fr) Procede de production photolytique de monoxyde d'azote
JP3507347B2 (ja) 腐植土抽出物質含有水性液
WO2003047533A2 (fr) Composition pour le traitement de la surface de la peau
DE10006578C2 (de) Verwendung von kompatiblen Soluten als Inhibitoren des enzymatischen Abbaus von makromolekularen Biopolymeren
EP2358642B2 (fr) Clinoptilolite ou mélanges comprenant du clinoptilolite
WO2012022659A2 (fr) Effet synergique de modulateurs du métabolisme de no et de la nadph oxydase lors de la sensibilisation de cellules tumorales
EP0535317B1 (fr) Médicament pour le traitement de disfonctionnement nerveux et d'états d'excitation
Sukul et al. Reduction in the number of infective Trichinella spiralis larvae in mice by use of homeopathic drugs
EP0065246B1 (fr) Procédé de production de substances actives anaboliques favorisant la respiration et de faible poids moléculaire pour des fins prophylactiques, thérapeutiques et pour des techniques de culture de cellules et de tissus
DE102006037632A1 (de) Mikrobiologische Mischung zum Auftragen auf eine Hautoberfläche, Verfahren zum Auftragen einer solchen Mischung auf einer Hautoberfläche, sowie eine Anordnung zum Durchführen des Verfahrens
DE2715893A1 (de) Verfahren zur selektiven inaktivierung von amylase
DE1922601A1 (de) Neue Enzyminhibitoren und ihre Herstellung
EP1687238B1 (fr) Composes chlores reactifs, leurs derives, anions et sels, procedes pour les produire et leur utilisation
KR20120067462A (ko) 옻나무 추출액을 함유하는 숙취해소음료 및 그 제조방법
DE3712505A1 (de) Salzmischung zur behandlung der schuppenflechte (psoriasis) und anderer hautkrankheiten
CH636499A5 (en) Process for the preparation of germanium-containing algae
DE60219770T2 (de) Krebsmittel
DE1492823A1 (de) Verfahren zum Herstellen von Milchprodukten
DE3617368C2 (de) Verfahren zur Herstellung eines stickstoffhaltigen Polysaccharids
DE102009040571A1 (de) Diätetikum
WO2004043868A1 (fr) Procede d'epuration d'eaux usees
EP2776067B1 (fr) Composition pour le diagnostic et le traitement photodynamique des tumeurs
DE102022002236A1 (de) Katerfreies Bier und sein Herstellungsverfahren

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP